Research progress on drug resistance of anti-varicella-zoster virus drugs.
10.3760/cma.j.cn112150-20220825-00839
- VernacularTitle:抗水痘-带状疱疹病毒药物的耐药研究进展
- Author:
Ya Li ZHANG
1
;
Wen Zhe SU
2
;
Chao Feng MA
3
;
Song Tao XU
4
Author Information
1. School of Public Health, Shaanxi University of Chinese Medicine, Xianyang 712000, China.
2. Department of Viral Immunization, Guangzhou Center for Disease Control and Prevention, Guangzhou 510000, China.
3. School of Public Health, Shaanxi University of Chinese Medicine, Xianyang 712000, China Department of Virology, Xi'an Center for Disease Control and Prevention, Xi'an 710000, China.
4. State Key Laboratory for Infectious Disease Prevention and Control,National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206,China.
- Publication Type:Journal Article
- MeSH:
Humans;
Herpesvirus 3, Human;
Herpes Zoster;
Chickenpox;
Antiviral Agents/therapeutic use*;
Drug Resistance
- From:
Chinese Journal of Preventive Medicine
2023;57(2):259-267
- CountryChina
- Language:Chinese
-
Abstract:
Varicella-zoster virus (VZV) causes chickenpox when it first infects humans, and the virus may reactivate in adulthood and cause herpes zoster (HZ). Broad-spectrum antiviral drugs are one of the treatments for varicella and herpes zoster, but the emergence of drug resistance poses many challenges to this treatment and increases the burden of disease on patients. This paper discusses the resistance mechanisms, resistance sites and resistance detection methods of anti-VZV drugs in order to help further research on new anti-VZV targets, new drugs and monitoring of resistance to existing drugs.
